[Congressional Record Volume 167, Number 107 (Monday, June 21, 2021)]
[Senate]
[Pages S4657-S4658]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
STATEMENTS ON INTRODUCED BILLS AND JOINT RESOLUTION
By Mr. REED:
S. 2145. A bill to ensure that irresponsible corporate executives,
rather than shareholders, pay fines and penalties; to the Committee on
Banking, Housing, and Urban Affairs.
Mr. REED. Mr. President, today I am reintroducing the Corporate
Management Accountability Act, which asks each publicly traded company
to disclose its policies on whether senior executives or shareholders
bear the costs of paying the company's fines and penalties.
In 2014, William Dudley, then the President of the Federal Reserve
Bank of New York, gave a speech titled ``Enhancing Financial Stability
by Improving Culture in the Financial Services Industry.'' In this
speech, President Dudley said, ``in recent years, there have been
ongoing occurrences of serious professional misbehavior, ethical lapses
and compliance failures at financial institutions. This has resulted in
a long list of large fines and penalties and to a lesser degree than I
would have desired employee dismissals and punishment . . . The pattern
of bad behavior did not end with the financial crisis, but continued
despite the considerable public sector intervention that was necessary
to stabilize the financial system. As a consequence, the financial
industry has largely lost the public trust.''
Since 2009, banks around the world have paid $394 billion in
penalties, according to the Boston Consulting Group (BCG). This is an
increase of $22 billion from the last time I introduced this
legislation. It has been evident that simply fining and penalizing
financial institutions at the corporate level is not enough to deter
bad actors. Senior executives, many of whom are all too eager to take
credit for a company's good news, must also take more responsibility
for the bad news, especially if it is true that the buck stops with
them.
According to Professor Peter J. Henning, who also writes the White
Collar Watch column for the New York Times, ``a problem in holding
individuals accountable for misconduct in an organization is the
disconnect between the actual decisions and those charged with
overseeing the company, so that executives and corporate boards usually
plead ignorance about an issue until it is too late.''
The Corporate Management Accountability Act I am reintroducing today
is one attempt at helping to solve this problem. The bill simply asks
publicly traded companies to disclose whether they expect senior
executives or shareholders to pay the cost of corporate fines or
penalties. This proposal has been supported by University of Minnesota
Law School Professors Claire Hill and Richard Painter, who also served
as President George W. Bush's chief ethics lawyer, as well as Americans
for Financial Reform.
I urge all my colleagues to join this legislative effort to hold
senior executives accountable for their actions.
______
By Ms. COLLINS (for herself and Mrs. Shaheen):
S. 2146. A bill to establish within the Office of the Secretary of
Health and Human Services a special task force on ensuring Medicare
beneficiary access to innovative diabetes technologies and services; to
the Committee on Finance.
Mr. REED. Mr. President, today I am reintroducing the Stronger
Enforcement of Civil Penalties Act along with Senator Grassley and
Senator Leahy. This bill will help securities regulators better protect
investors and demand greater accountability from market players. Even
in the midst of an unprecedented public health and economic emergency,
we continue to see calculated wrongdoing by some on Wall Street, and
without the consequence of meaningful penalties to serve as an
effective deterrent, I worry this disturbing culture of misconduct will
persist.
The amount of penalties the Securities and Exchange Commission (SEC)
can fine an institution or individual is restricted by statute. During
hearings I held in 2011 as Chairman of the Banking Committee's
Securities, Insurance, and Investment Subcommittee, I learned how this
limitation significantly interferes with the SEC's ability to execute
its enforcement duties. At that time, a Federal judge had criticized
the SEC for not obtaining a larger settlement against Citigroup, a
major actor in the financial crisis that settled with the agency in an
amount that was far below the cost the bank had inflicted on investors.
The SEC indicated that a statutory prohibition against levying a larger
penalty led to the low settlement amount. Indeed, then SEC Chairman
Mary L. Schapiro in 2011 also explained that ``the Commission's
statutory authority to obtain civil monetary penalties with appropriate
deterrent effect is limited in many circumstances.''
The bipartisan bill we are reintroducing aims to update the SEC's
outdated civil penalties statutes. This bill strives to make potential
and current offenders think twice before engaging in misconduct by
raising the maximum statutory civil monetary penalties, directly
linking the size of the penalties to the amount of losses suffered by
victims of a violation, and substantially increasing the financial
stakes for serial offenders of our nation's securities laws.
Specifically, our bill would broaden the SEC's options to tailor
penalties to the particular circumstances of a given violation. In
addition to raising the per violation caps for severe, or ``third
tier,'' violations to $1 million per offense for individuals and $10
million per offense for entities, the legislation would also give the
SEC more options to collect greater penalties based on the ill-gotten
gains of the violator or on the financial harm to investors.
Our bill also seeks to deter repeat offenders on Wall Street through
two provisions. The first would authorize the SEC to triple the penalty
cap applicable to recidivists who have been held either criminally or
civilly liable for securities fraud within the previous five years. The
second would allow the SEC to seek a civil penalty against those who
violate existing federal court or SEC orders, an approach that would be
more efficient, effective, and flexible than the current civil contempt
remedy. These updates would greatly enhance the SEC's ability to levy
robust penalties against repeat offenders.
According to the SEC's FY 2022 Congressional Budget Justification,
``the SEC is responsible for reviewing the disclosures and financial
statements of more than 7,400 reporting companies.'' The SEC further
notes that a ``record 67 million U.S. families held direct and indirect
stock holdings in 2019, up 13 percent from 2010,'' and the agency is
``charged with overseeing approximately $100 trillion in annual
securities trading on U.S. equity markets and the activities of more
than 28,000 registered entities.'' All of our constituents deserve a
strong regulator that has the necessary tools to go after fraudsters
and pursue the difficult cases arising from our increasingly complex
financial markets. The Stronger Enforcement of Civil Penalties Act will
enhance the SEC's ability to demand meaningful accountability from Wall
Street, which in turn will increase transparency and confidence in our
financial system. I urge our colleagues to support this important
bipartisan legislation.
______
By Mr. REED (for himself, Mr. Grassley, and Mr. Leahy):
S. 2147. A bill to enhance civil penalties under the Federal
securities laws, and for other purposes; to the Committee on Banking,
Housing, and Urban Affairs.
Mrs. SHAHEEN. Mr President, I come to the floor today to join my
colleague Senator Collins from Maine, who will be here shortly, who is
also my cochair of the Diabetes Caucus, to reintroduce the Improving
Medicare Beneficiary Access to Innovative Diabetes Technologies Act.
This is legislation that would establish a task force to provide
recommendations to help
[[Page S4658]]
guide Medicare's decisions on coverage and payment for new technologies
to improve the lives of people with diabetes.
I have had the opportunity to see the challenges that families with
members who have type 1 diabetes face. My granddaughter, my oldest
granddaughter, has type 1 diabetes, and I know the challenges her
family faces navigating a complex web of insurance coverage rules for
technologies. Anytime a new technology comes out that would benefit
her, to get the insurance companies to adopt those technologies is a
huge challenge, and it requires hours of phone time with the insurance
company, trying to persuade them that they should provide the coverage.
Well, we know that these insurance companies often base their
coverage and reimbursement rules on Medicare. That is why it is so
important for the Medicare Program to keep pace with the development of
new diabetes technologies and devices.
I appreciate the opportunity to work with Senator Collins on a
regular basis in the Diabetes Caucus. In 2017, we were successful in
pressing Medicare to cover continuous glucose monitors, something that
seems like an obvious choice given the difference that those CGMs can
make for people who have diabetes and ensuring that their blood sugar
stays stable. We have also worked together to ensure that Medicare
provides flexibility so that patients can use smartphone apps with
their continuous glucose monitors.
In the years to come, we need Medicare to make progress toward
covering the artificial pancreas, a landmark development that will be
the most significant change for people with diabetes since insulin was
discovered, but to do this, we shouldn't have to resign ourselves to
this piecemeal approach to Medicare coverage that requires continual
pressure from Congress and advocates.
We need an independent body, like the one that is identified in our
legislation, to help provide recommendations to Medicare so that its
coverage of new technologies can adapt more quickly as innovation
advances. That is why I am proud to be here on the floor and proud to
join Senator Collins in reintroducing this bill. I hope my colleagues
will take a look at it, decide that it merits passage, and work with us
to get that done.
My colleague has arrived on the floor.
Senator Collins, I was just saying that I was very proud to be able
to join you in reintroducing this legislation, and hopefully this
session, we will be able to get it done. Thank you for your leadership,
and I look forward to hearing your comments and to working to get this
passed.
The PRESIDING OFFICER. The Senator from Maine.
Ms. COLLINS. Mr. President, first, let me thank my colleague from New
Hampshire, Senator Shaheen, for her extraordinary commitment and
leadership as my fellow cochair of the Senate Diabetes Caucus. We are
introducing a bill to improve access to innovative diabetes
technologies for our seniors and other Medicare beneficiaries. Our bill
would create a special task force at the Department of Health and Human
Services to examine and resolve barriers that seniors face in accessing
the latest diabetes management technologies.
New diabetes technologies, such as the artificial pancreas and
implantable continuous glucose monitoring systems, allow those who are
living with diabetes to better manage their glycemic levels, assess
needed therapy on a timely basis, and adhere better to treatment
regimes. These technological advances make diabetes easier to manage
and therefore improve the health of people with diabetes.
The market arrival of cutting-edge diabetes technologies is something
we all celebrate; however, oftentimes we are finding that patients do
not realize the full benefits because many of our Nation's seniors find
the new technologies to be difficult or impossible for them to afford.
I have heard from numerous seniors who, when transitioning from
employer-provided insurance to Medicare, were shocked to learn that the
technologies they had relied upon for years to manage their diabetes
are no longer covered because they now have lost their employer-
provided insurance, which did cover these technologies, and instead are
being covered by Medicare. For example, one Mainer unfortunately had to
face the reality that Medicare's coverage denial of a particular sensor
that he needed for his insulin pump meant paying up to $8,000 out-of-
pocket each year if he wants to continue with his current treatment. He
wrote:
Because I am now 65, I am denied care that was available
when I was 64.
He continued:
This approach not only puts me at risk but is quite likely
not cost effective. While the sensors are expensive, the cost
of ambulance calls and hospitalizations . . . is certainly
more.
I could not say it better. It makes no sense for this individual, who
has aged into the Medicare system, to lose coverage that he had and
relied upon and used successfully to control his diabetes.
To better support the adoption of these technologies, our bill would
require HHS to create a special task force on coverage and payment for
innovative diabetes technologies that would bring all stakeholders--
from patients to device manufacturers, to government officials and
healthcare professionals who are making coverage decisions--to the
table. The task force would identify and plan for changes in Medicare
coverage and payment policies to ensure that Medicare beneficiaries
have access to the latest treatments, to the innovations that are
currently available, as well as those that are in the pipeline. The
task force would also be tasked with developing strategies for
supporting adoption of these technologies.
This effort builds on our past advocacy to improve the day-to-day
life of individuals with diabetes. In January 2017, in response to the
bipartisan effort that Senator Shaheen and I have led, CMS first
approved the use of continuous glucose monitors. We also successfully
urged CMS last year to support the use of smartphone apps in
conjunction with continuous glucose monitors. These are proven
lifesaving devices that are relied upon by people with diabetes to
provide them with realtime measurements of their glucose levels. This
information is key to preventing costly--sometimes deadly--diabetes
complications.
While I am pleased that our advocacy has helped spur these policy
changes, I remain frustrated that too often Medicare lags behind
commercial insurers. Greater adoption of these new diabetes techniques
can help address the explosive growth in the financial and human toll
of diabetes. Diabetes accounts for an extraordinary one-in-three
dollars in Medicare spending. It is paramount that we encourage HHS to
adopt a more cost-effective and compassionate approach to treating this
chronic disease that affects more than 30 million Americans.
The Improving Medicare Beneficiary Access to Innovative Diabetes
Technologies Act encourages a proactive approach to diabetes coverage
and payment. I encourage my colleagues to support our efforts.
Again, thanks to my partner Senator Shaheen for her leadership in
this area.
____________________